Change institution
Advanced Nano and Microtechnologies Advanced Materials Structural Biology Gen. and Prot. of Plant Systems Molecular Medicine Brain and Mind Research Molecular Vet. Medicine

Prof. Jiří Mayer

Senior Researcher
Email: ,
Phone: +420 54949 1301, +420 532 233 643, +420 532 233 603
Research Group: Medical Genomics - Šárka Pospíšilová

2017

  • KANTOROVA, B; MALCIKOVA, J; BRAZDILOVA, K; BORSKY, M; PLEVOVA, K; SMARDOVA, J; RADOVA, L; TOM, N; TRBUSEK, M; DIVISKOVA, E; FRANCOVA, HS; NAVRKALOVA, V; DOUBEK, M; BRYCHTOVA, Y; MAYER, J; POSPISILOVA, S, 2017:Single cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients. BRITISH JOURNAL OF HAEMATOLOGY 178 (6), p. 979 - 982.
  • LEDEREROVA, A; KOZLOVA, V; VAKULOVA, V; DOUBEK, M; MAYER, J; POSPISILOVA, S; SMIDA, M, 2017:B CELLS RESISTANT TO CD20 MONOCLONAL ANTIBODIES DISPLAY SPECIFIC ALTERATIONS IN GENE EXPRESSION PROFILE. HAEMATOLOGICA 102 , p. 709 - 709.
  • PAVLASOVA, G; BORSKY, M; SVOBODOVA, V; MUSILOVA, K; CERNA, K; SEDA, V; OSICKOVA, J; BRYCHTOVA, Y; DOUBEK, M; POSPISILOVA, S; MAYER, J; MRAZ, M, 2017:BCR SIGNALLING PROFICIENT CHRONIC LYMPHOCYTIC LEUKAEMIA B CELLS ARE PRONE TO RITUXIMAB MEDIATED ELIMINATION IN VIVO. HAEMATOLOGICA 102 , p. 412 - 412.

2016

  • BEZDICEK, M; LENGEROVA, M; RICNA, D; WEINBERGEROVA, B; KOCMANOVA, I; VOLFOVA, P; DRGONA, L; POCZOVA, M; MAYER, J; RACIL, Z, 2016:Rapid detection of fungal pathogens in bronchoalveolar lavage samples using panfungal PCR combined with high resolution melting analysis. MEDICAL MYCOLOGY 54 (7), p. 714 - 724.
  • CORTES, JE; SAGLIO, G; KANTARJIAN, HM; BACCARANI, M; MAYER, J; BOQUE, C; SHAH, NP; CHUAH, C; CASANOVA, L; BRADLEY-GARELIK, B; MANOS, G; HOCHHAUS, A, 2016:Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. JOURNAL OF CLINICAL ONCOLOGY 34 (20), p. 2333 - U54.
  • CULEN, M; BORSKY, M; NEMETHOVA, V; RAZGA, F; SMEJKAL, J; JURCEK, T; DVORAKOVA, D; ZACKOVA, D; WEINBERGEROVA, B; SEMERAD, L; SADOVNIK, I; EISENWORT, G; HERRMANN, H; VALENT, P; MAYER, J; RACIL, Z, 2016:Quantitative assessment of the CD26+leukemic stem cell compartment in chronic myeloid leukemia: Patient-subgroups, prognostic impact, and technical aspects. ONCOTARGET 7 (22), p. 33016 - 33024.
  • GREIL, R; OBRTLIKOVA, P; SMOLEJ, L; KOZAK, T; STEURER, M; ANDEL, J; BURGSTALLER, S; MIKUSKOVA, E; GERCHEVA, L; NOSSLINGER, T; PAPAJIK, T; LADICKA, M; GIRSCHIKOFSKY, M; HRUBISKO, M; JAGER, U; FRIDRIK, M; PECHERSTORFER, M; KRALIKOVA, E; BURCOVEANU, C; SPASOV, E; PETZER, A; MIHAYLOV, G; RAYNOV, J; OEXLE, H; ZABERNIGG, A; FLOCHOVA, E; PALASTHY, S; STEHLIKOVA, O; DOUBEK, M; ALTENHOFER, P; PLEYER, L; MELCHARDT, T; KLINGLER, A; MAYER, J; EGLE, A, 2016:Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. LANCET HAEMATOLOGY 3 (7), p. E317 - E329.
  • HO, AD; SCHETELIG, J; BOCHTLER, T; SCHAICH, M; SCHAFER-ECKART, K; HANEL, M; ROSLER, W; EINSELE, H; KAUFMANN, M; SERVE, H; BERDE, WE; STELLJES, M; MAYER, J; REICHLE, A; BALDUS, CD; SCHMITZ, N; KRAMER, M; ROLLIG, C; BORNHAUSER, M; THIEDE, C; EHNINGER, G, 2016:Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 22 (3), p. 462 - 469.
  • KUBESOVA, B; PAVLOVA, S; MALCIKOVA, J; KABATHOVA, J; RADOVA, L; TOM, N; TICHY, B; PLEVOVA, K; KANTOROVA, B; FIEDOROVA, K; KISSOVA, J; GISSLINGER, B; GISSLINGER, H; MAYER, J; KRALOVICS, R; POSPISILOVA, S; DOUBEK, M, 2016:Low-Burden TP53 Mutations Occur in Chronic Phase of Myeloproliferative Neoplasms Regardless of Hydroxyurea Administration, Disease Type, and JAK2 Status. BLOOD 128 (22)
  • SMIDA, M; KOZLOVA, V; VAKULOVA, V; LEDEREROVA, A; DOUBEK, M; MAYER, J; POSPISILOVA, S, 2016:Cellular Mechanisms Regulating CD20 As a Target of Monoclonal Antibody Therapy in B-Lymphoid Malignancies. BLOOD 128 (22)

2015

  • BRAZDILOVA, K; PLEVOVA, K; FRANCOVA, HS; KOCKOVA, H; CHMELIKOVA, M; BORSKY, M; BURCKOVA, K; KANTOROVA, B; TICHY, B; SKABRAHOVA, H; BRYCHTOVA, Y; MAYER, J; DOUBEK, M; POSPISILOVA, S, 2015:Single Cell Analysis of IG Genes in CLL: Cases with Multiple IGH Rearrangements Are Constituted of Several Independent Clones Even When Indistinguishable By Flow Cytometry. BLOOD 126 (23)
  • JASKOVA, Z; MALCIKOVA, J; SMARDOVA, J; BRYCHTOVA, Y; MAYER, J; TRBUSEK, M, 2015:ELIMINATION OF MUTATED P53 PROTEIN AND INDUCTION OF P53 DOWNSTREAM GENES IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS USING PRIMA-1MET. HAEMATOLOGICA 100 , p. 414 - 414.
  • KANTOROVA, B; MALCIKOVA, J; BRAZDILOVA, K; BORSKY, M; PLEVOVA, K; SMARDOVA, J; TRBUSEK, M; BRYCHTOVA, Y; DOUBEK, M; MAYER, J; POSPISILOVA, S, 2015:Single Cell Analysis Proves the Coexistence of NOTCH1 and TP53 Mutations within the Same Cancer Cells in Patients with Chronic Lymphocytic Leukemia. BLOOD 126 (23)
  • KOTASKOVA, J; MALCIKOVA, J; DIVISKOVA, E; PAVLOVA, S; MEJSTRIKOVA, S; VRANOVA, V; PLEVOVA, K; PLESINGEROVA, H; DOUBEK, M; MAYER, J; POSPISILOVA, S, 2015:13Q DELETION IS PREDOMINANT CYTOGENETIC ABERRATION NEWLY AQUIRED DURING CHRONIC LYMPHOCYTIC LEUKEMIA COURSE IRRESPECTIVE OF DISEASE ACTIVITY AND TREATMENT STATUS. HAEMATOLOGICA 100 , p. 417 - 418.
  • MALCIKOVA, J; STANO-KOZUBIK, K; TICHY, B; KANTOROVA, B; PAVLOVA, S; TOM, N; RADOVA, L; SMARDOVA, J; PARDY, F; DOUBEK, M; BRYCHTOVA, Y; MRAZ, M; PLEVOVA, K; DIVISKOVA, E; OLTOVA, A; MAYER, J; POSPISILOVA, S; TRBUSEK, M, 2015:Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. LEUKEMIA 29 (4), p. 877 - 885.
  • PAVLASOVA, G; SEDA, V; BORSKY, M; CERNA, K; OSICKOVA, J; MAYER, J; POSPISILOVA, S; DAVIDS, MS; BROWN, JR; MRAZ, M, 2015:Microenvironmental Interactions up-Regulate CD20 Expression in CLL B Cells through the CXCR4/SDF-1 Axis: Implications for CD20-Targeting Antibodies and the Use of BCR-Inhibitors in Combination. BLOOD 126 (23)
  • TOM, N; MALCIKOVA, J; RADOVA, L; KANTOROVA, B; PARDY, F; PAVLOVA, S; PAL, K; MRAZ, M; TICHY, B; DOUBEK, M; BRYCHTOVA, Y; PLEVOVA, K; MAYER, J; TRBUSEK, M; POSPISILOVA, S, 2015:MUTATIONS IN THE TP53 GENE SHOW FEATURES OF SOMATIC HYPERMUTATION PROCESS WITH PROMINENT DIFFERENCE BETWEEN IGHV MUTATED AND UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA. HAEMATOLOGICA 100 , p. 224 - 225.
  • ZEMANOVA, J; PARUCH, K; KREJCI, L; SOUCEK, K; HYLSE, O; BOUDNY, M; BORSKY, M; OSICKOVA, J; KHIRSARIYA, P; SEBEJOVA, L; NAVRKALOVA, V; MALCIKOVA, J; DIVISKOVA, E; BRYCHTOVA, Y; MAYER, J; TRBUSEK, M, 2015:CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE HIGHLY SUSCEPTIBLE TO DIRECT INHIBITION OF CHECKPOINT KINASE 1. HAEMATOLOGICA 100 , p. 417 - 417.

2014

  • DOUBEK, M; SROVNAL, J; PLEVOVA, K; TRIZULJAK, J; BRYCHTOVA, Y; SEMERAD, L; LETALOVA, E; BENEDIKOVA, A; MAYER, J; HAJDUCH, M; POSPISILOVA, S, 2014:ANALYSIS OF MERKEL CELL POLYOMAVIRUS PROGNOSTIC SIGNIFICANCE IN CHRONIC LYMPHOCYTIC LEUKEMIA. HAEMATOLOGICA 99 , p. 325 - 325.
  • HOFFMANN, V; LINDOERFER, D; THALER, J; LABAR, B; MELANTHIOU, F; MAYER, J; EVERAUS, H; PORKKA, K; GUILLHOT, J; SCHUBERT-FRITSCHLE, G; CASTAGNETTI, F; LEJNIECE, S; GRISKEVICIUS, L; THIELEN, N; HELLMANN, A; TURKINA, A; ZARITSKEY, A; BOGDANOVIC, AD; INDRAK, K, 2014:THE EUTOS POPULATION BASED REGISTRY - INCIDENCES OF CML ACROSS EUROPE. HAEMATOLOGICA 99 , p. 72 - 72.
  • LENGEROVA, M; RACIL, Z; HRNCIROVA, K; KOCMANOVA, I; VOLFOVA, P; RICNA, D; BEJDAK, P; MOULIS, M; PAVLOVSKY, Z; WEINBERGEROVA, B; TOSKOVA, M; MAYER, J, 2014:Rapid Detection and Identification of Mucormycetes in Bronchoalveolar Lavage Samples from Immunocompromised Patients with Pulmonary Infiltrates by Use of High-Resolution Melt Analysis. JOURNAL OF CLINICAL MICROBIOLOGY 52 (8), p. 2824 - 2828.
  • LINDOERFER, D; HOFFMANN, VS; ROSTI, G; CASTAGNETTI, F; SAUSSELE, S; GUILHOT, J; SIMONSSON, B; STEEGMANN, JL; MAYER, J; INDRAK, K; TURKINA, AG; ZARITSKEY, A; LABAR, B; ZUPAN, IP; THIELEN, N; CLARK, RE; THALER, J; MELANTHIOU, F; EVERAUS, H; PORKKA, K; BOGDA, 2014:THE EUTOS POPULATION-BASED REGISTRY: EVALUATION OF BASELINE CHARACTERISTICS AND FIRST TREATMENT CHOICES OF 2983 NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS FROM 20 EUROPEAN COUNTRIES. HAEMATOLOGICA 99 , p. 238 - 239.
  • NAVRKALOVA, V; MARECKOVA, A; JANIKOVA, A; DOUBEK, M; MAYER, J; POSPISILOVA, S; TRBUSEK, M, 2014:INCORPORATION OF NEXT-GENERATION SEQUENCING INTO ATM GENE ANALYSIS IN PATIENTS WITH CLL AND MCL. HAEMATOLOGICA 99 , p. 312 - 312.
  • ROBESOVA, B; BAJEROVA, M; LISKOVA, K; SKRICKOVA, J; TOMISKOVA, M; POSPISILOVA, S; MAYER, J; DVORAKOVA, D, 2014:TaqMan based real time PCR assay targeting EML4-ALK fusion transcripts in NSCLC. LUNG CANCER 85 (1), p. 25 - 30.
  • VERNER, J; TRBUSEK, M; CHOVANCOVA, J; SKABRAHOVA, H; JASKOVA, Z; MOULIS, M; FOLBER, F; HALOUZKA, R; MAYER, J; POSPISILOVA, S; DOUBEK, M, 2014:NOD/SCID GAMMA XENOGRAFT MODEL OF B-CELL MALIGNANCIES USING TP53-AND/OR ATM-DEFICIENT CELL LINES. HAEMATOLOGICA 99 , p. 312 - 313.

2013

  • BACCARANI, M; DEININGER, MW; ROSTI, G; HOCHHAUS, A; SOVERINI, S; APPERLEY, JF; CERVANTES, F; CLARK, RE; CORTES, JE; GUILHOT, F; HJORTH-HANSEN, H; HUGHES, TP; KANTARJIAN, HM; KIM, DW; LARSON, RA; LIPTON, JH; MAHON, FX; MARTINELLI, G; MAYER, J; MULLER, MC; , 2013:European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. BLOOD 122 (6), p. 872 - 884.
  • FINK, AM; BOTTCHER, S; RITGEN, M; FISCHER, K; PFLUG, N; EICHHORST, B; WENDTNER, CM; WINKLER, D; BUHLER, A; ZENZ, T; STAIB, P; MAYER, J; HENSEL, M; HOPFINGER, G; WENGER, M; FINGERLE-ROWSON, G; DOHNER, H; KNEBA, M; STILGENBAUER, S; BUSCH, R; HALLEK, M, 2013:Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab. LEUKEMIA 27 (9), p. 1949 - 1952.
  • HOFFMANN, VS; BACCARANI, M; LINDOERFER, D; CASTAGNETTI, F; TURKINA, A; ZARITSKY, A; HELLMANN, A; PREJZNER, W; STEEGMANN, JL; MAYER, J; INDRAK, K; COLITA, A; ROSTI, G; PFIRRMANN, M, 2013:The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. LEUKEMIA 27 (10), p. 2016 - 2022.
  • RACIL, Z; RAZGA, F; DRAPALOVA, J; BURESOVA, L; ZACKOVA, D; PALACKOVA, M; SEMERAD, L; MALASKOVA, L; HALUZIK, M; MAYER, J, 2013:Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. HAEMATOLOGICA 98 (10)

2012

  • JANIKOVA, A; MARECKOVA, A; DVORAKOVA, D; BORTLICEK, Z; TICHY, B; NAVRATIL, M; KRAL, Z; POSPISILOVA, S; MAYER, J, 2012:A real-time (PCR) for a real life ...? Quantitative evaluation of BCL2/IGH in follicular lymphoma and its implications for clinical practice. EXPERIMENTAL HEMATOLOGY 40 (7), p. 528 - 539.
  • KOZUBIK, KS; MALCIKOVA, J; TRBUSEK, M; TOM, N; DOUBEK, M; BRYCHTOVA, Y; SMARDOVA, J; MAYER, J; POSPISILOVA, S; TICHY, B, 2012:Clonal Selection of TP53 Mutations in Chronic Lymphocytic Leukaemia Detected by Ultra-deep Pyrosequencing. EUROPEAN JOURNAL OF CANCER 48 , p. S146 - S146.
  • LENGEROVA, M; KOCMANOVA, I; RACIL, Z; HRNCIROVA, K; POSPISILOVA, S; MAYER, J; NAJVAR, LK; WIEDERHOLD, NP; KIRKPATRICK, WR; PATTERSON, TF, 2012:Detection and Measurement of Fungal Burden in a Guinea Pig Model of Invasive Pulmonary Aspergillosis by Novel Quantitative Nested Real-Time PCR Compared with Galactomannan and (1,3)-beta-D-Glucan Detection. JOURNAL OF CLINICAL MICROBIOLOGY 50 (3), p. 602 - 608.
  • MRAZ, M; DOLEZALOVA, D; PLEVOVA, K; KOZUBIK, KS; MAYEROVA, V; CERNA, K; MUSILOVA, K; TICHY, B; PAVLOVA, S; BORSKY, M; VERNER, J; DOUBEK, M; BRYCHTOVA, Y; TRBUSEK, M; HAMPL, A; MAYER, J; POSPISILOVA, S, 2012:MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. BLOOD 119 (9), p. 2110 - 2113.

2011

  • TRBUSEK, M; SMARDOVA, J; MALCIKOVA, J; SEBEJOVA, L; DOBES, P; SVITAKOVA, M; VRANOVA, V; MRAZ, M; FRANCOVA, HS; DOUBEK, M; BRYCHTOVA, Y; KUGLIK, P; POSPISILOVA, S; MAYER, J, 2011:Missense Mutations Located in Structural p53 DNA-Binding Motifs Are Associated With Extremely Poor Survival in Chronic Lymphocytic Leukemia. JOURNAL OF CLINICAL ONCOLOGY 29 (19), p. 2703 - 2708.
  • WALEWSKI, J; PASZKIEWICZ-KOZIK, E; WARSZEWSKA, A; BORSARU, G; MOICEAN, A; HELLMANN, A; MAYER, J; HAUNS, B; MAIS, A; HENNING, SW; HENTSCH, B, 2011:Final Results of the Phase II SAPHIRE Trial of Resminostat (4SC-201) in Patients with Relapsed/Refractory Hodgkin Lymphoma. BLOOD 118 (21), p. 1149 - 1149.

2010

  • KOTASKOVA, JANA; TICHY, BORIS; TRBUSEK, MARTIN; FRANCOVA, HANA SKUHROVA; KABATHOVA, JITKA; MALCIKOVA, JITKA; DOUBEK, MICHAEL; BRYCHTOVA, YVONA; MAYER, JIRI; POSPISILOVA, SARKA, 2010:High Expression of Lymphocyte-Activation Gene 3 (LAG3) in Chronic Lymphocytic Leukemia Cells Is Associated with Unmutated lmmunoglobulin Variable Heavy Chain Region (IGHV) Gene and Reduced Treatment-Free Survival. JOURNAL OF MOLECULAR DIAGNOSTICS 12 (3), p. 328 - 334.
  • MALCIKOVA, J; TICHY, B; DAMBORSKY, J; KABATHOVA, J; TRBUSEK, M; MAYER, J; POSPISILOVA, S, 2010:Analysis of the DNA-binding activity of p53 mutants using functional protein microarrays and its relationship to transcriptional activation. BIOLOGICAL CHEMISTRY 391 (2 III), p. 197 - 205.

2009

  • MRAZ, M., MALINOVA, K., KOTASKOVA, J., PAVLOVA, S., TICHY, B., MALCIKOVA, J., STANO-KOZUBIK, K., SMARDOVA, J., BRYCHTOVA, Y., DOUBEK, M., TRBUSEK, M., MAYER, J., POSPISILOVA, S., 2009:miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia 23 (6), p. 1159 - 1163.
Office 1:
Masarykova univerzita - CEITEC MU Kamenice 753/5, Brno, 625 00, office bud. A17/333
Office 2:
Masarykova univerzita Kamenice 753/5, Brno, 625 00
More CEITEC News ...
Dr. Ondrej Hovorka: Models of magnetic nanoparticles for biomedical applications

29. ledna 2018 9:46

Dr. Ondrej Hovorka: Models of magnetic nanoparticles for biomedical…

LECTURE: Dr. Ondrej Hovorka: Models of magnetic nanoparticles for biomedical applications

Advanced Materials and Nanotechnology Seminar Series 2018: Dr Andriy Marko

25. ledna 2018 18:21

Advanced Materials and Nanotechnology Seminar Series 2018: Dr Andriy…

WHEN: 30. 01. 2018 WHERE: CEITEC BUT, Purkynova 123, large meeting room SPEAKER: Dr Andriy Marko TALK: Advances in PELDOR…